Pathstone Holdings’s Verve Therapeutics VERV Stock Holding History

Pathstone Holdings’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-10,940	Closed	-$52.9K	–	2407
2024 Q3	$52.9K	Buy	+10,940	New	+$63.5K	﹤0.01%	2283

Other funds holding VERV

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Pathstone Holdings's VERV Position: Q4 2024 in Review

Pathstone Holdings sold out of Verve Therapeutics (VERV) in Q4 2024, closing a stake of 10,940 shares — an estimated $52.9K sold.

Pathstone Holdings first reported a position in VERV in Q3 2024 and held it in 1 quarter. The position peaked at $52.9K in Q3 2024. 166 funds tracked by Wall St. Rank hold VERV as of Q4 2024.

Pathstone Holdings reported no remaining Verve Therapeutics position as of Q4 2024 after selling out during the quarter.
Pathstone Holdings sold 10,940 Verve Therapeutics shares in Q4 2024, an estimated $52.9K.
Pathstone Holdings first reported a position in Verve Therapeutics in Q3 2024 and held it in 1 quarter.
Pathstone Holdings's Verve Therapeutics position peaked at $52.9K in Q3 2024.
166 funds tracked by Wall St. Rank held Verve Therapeutics as of Q4 2024.

Based on Pathstone Holdings's 13F filing for Q4 2024, filed 14 Feb 2025.